Y Intercept Hong Kong Ltd Acquires 6,585 Shares of LivaNova PLC $LIVN

Y Intercept Hong Kong Ltd increased its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 56.8% in the 1st quarter, HoldingsChannel.com reports. The firm owned 18,169 shares of the company’s stock after acquiring an additional 6,585 shares during the period. Y Intercept Hong Kong Ltd’s holdings in LivaNova were worth $1,155,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Millennium Management LLC boosted its stake in LivaNova by 17.3% in the 4th quarter. Millennium Management LLC now owns 3,484,082 shares of the company’s stock worth $214,376,000 after purchasing an additional 514,268 shares during the period. Wellington Management Group LLP raised its position in shares of LivaNova by 83.5% during the third quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after buying an additional 1,067,349 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of LivaNova by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 2,332,051 shares of the company’s stock worth $143,491,000 after buying an additional 34,812 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of LivaNova by 29.9% during the fourth quarter. AQR Capital Management LLC now owns 2,155,142 shares of the company’s stock worth $132,606,000 after acquiring an additional 496,165 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of LivaNova by 3.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,787,928 shares of the company’s stock worth $110,014,000 after acquiring an additional 66,755 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Francesco Bianchi sold 1,800 shares of LivaNova stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total value of $136,350.00. Following the completion of the transaction, the director owned 7,228 shares in the company, valued at approximately $547,521. The trade was a 19.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.35% of the stock is owned by insiders.

LivaNova Price Performance

LIVN stock traded up $0.04 during trading on Friday, hitting $82.56. 452,293 shares of the company’s stock traded hands, compared to its average volume of 711,226. LivaNova PLC has a 52 week low of $41.01 and a 52 week high of $85.27. The stock has a market capitalization of $4.54 billion, a price-to-earnings ratio of 42.34 and a beta of 0.86. The business has a fifty day simple moving average of $76.00 and a 200 day simple moving average of $68.33. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.11 and a current ratio of 1.33.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. The firm had revenue of $362.26 million during the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, research analysts expect that LivaNova PLC will post 3.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on LIVN. Barclays lifted their price target on shares of LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. KeyCorp raised their price objective on LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Monday, June 22nd. Weiss Ratings raised LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Mizuho boosted their target price on LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. Finally, Robert W. Baird dropped their price target on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Six analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $80.75.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.